A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Study of Ustekinumab in Adult Japanese Subjects With Severe Atopic Dermatitis
Phase of Trial: Phase II
Latest Information Update: 24 Mar 2017
Price : $35 *
At a glance
- Drugs Ustekinumab (Primary)
- Indications Atopic dermatitis
- Focus Therapeutic Use
- Sponsors Janssen Pharmaceutical KK
- 24 Mar 2017 Primary endpoint (Percent change from Baseline to Week 12 in the Eczema Area and Severity Index (EASI) score) has not been met,according to the results published in the British Journal of Dermatology.
- 24 Mar 2017 Results published in the British Journal of Dermatology
- 15 Feb 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.